Galavit, 50 mg 5 pcs.

Pharmacotherapeutic group:
Immunomodulatory and anti-inflammatory agent.
ATC code: L03, G02.
Pharmacological properties
Pharmacodynamics
The mechanism of action of the drug is associated with its ability to regulate the functional and metabolic activity of cells of innate and adaptive immunity (monocytes, macrophages, neutrophils, natural killers, etc.). Galavit normalizes phagocytic activity of monocytes/macrophages, bactericidal activity of neutrophils and cytotoxic activity of NK-cells. At the same time restoring the reduced activity of innate and adaptive immunity cells, the preparation increases resistance of the organism to infectious diseases.
Besides, Galavit normalizes antibody formation, indirectly stimulates production of endogenous interferons (IFN-α, IFN-γ), increases functional activity (affinity) of antibodies.
In inflammatory diseases the drug reversibly inhibits excessive synthesis of tumor necrosis factor-α, interleukin-1, interleukin-6 and other pro-inflammatory cytokines for 6-8 hours. Their level determines the degree of inflammatory reactions, their cyclic pattern as well as severity of intoxication.
Galavit decreases production of reactive oxygen species by hyperactivated macrophages, thereby reducing the level of oxidative stress and protecting tissues and organs from the damaging effects of radicals.
Normalization of excessively high functional activity of phagocytic cells leads to the restoration of their antigen-presenting and regulatory function, reducing the level of autoaggression.
The drug has no allergic, mutagenic, embryotoxic, teratogenic and carcinogenic action.
Pharmacokinetics
It is eliminated from the body mainly through the kidneys. After intramuscular injection half-life is 30-40 minutes. The main pharmacological effects are observed within 72 hours.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Pregnancy use